Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week Published: Oct 23, 2020 | Tags: Akebia, Results, Vadadustat, P-lll, INNO2VATE Global Study, Anemia, Chronic Kidney Disease Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020 Published: Oct 22, 2020 […]Read More
Shots: Daiichi Sankyo to conduct two-part P-I study assessing U3-1402+ Tagrisso as both a 1L and 2L dual regimen in patients with advanced or mNSCLC with an EGFR exon 19 deletion or L858R mutation The dose-escalation part will assess the safety & tolerability of different dosing combinations of dual regimen to determine the recommended dose […]Read More
Shots: The new agreement involves, Daiichi to get royalties on sales of Movantik plus payments each year starting from 2021 to 2023. RedHill to take care of all the responsibilities and costs to commercialize Movantik in the US. Additionally, under a subscription agreement Daiichi will get 283,387 shares in RedHill Biopharma as partial consideration in […]Read More
Shots: Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical, translational, and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively The research program includes two P-II studies evaluating the efficacy, safety, and markers of response and resistance to DS-1062 & patritumab deruxtecan in […]Read More
Shots: Following the AstraZeneca’s discussion with the Japanese government to introduce COVID-19 vaccine in Japan, Daiichi Sankyo has advanced its conversation with AstraZeneca to formulate the vaccine, including vial filling, packaging, and storage Daiichi Sankyo plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities. The collaboration allows AstraZeneca to reach […]Read More
Shots: The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer, prior treated with 2L standard therapies. Results: ORR (45.3%); DCR (83.0%); PFS (6.9mos.); subgroup patients including patients with treated with a prior anti-HER2 regimen, ORR (43.8%) with a median treatment duration of 4.8mos. […]Read More
1. BMS Reports EMA’s Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Published: May 22, 2020 | Tags: bb2121, BMS ,CC-486, EMA, ide-cel Idecabtagene, Vicleucel MAA 2. Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India Published: May 21, 2020 | Tags: Gilead, Plans, Submit, MAA, CDSCO, Remdesivir, COVID-19, […]Read More
Shots: The US FDA’s ODD is based on P-II DESTINY-Gastric01 study assessing Enhertu (6.4 mg/kg, q3w) vs CT in 188 patients in a ratio (2:1) with HER2-expressing, advanced gastric cancer, progressed with 2+ prior treatment regimens including 5-FU, Pt. CT and trastuzumab The study demonstrated improvement in ORR & OS and will be presented at […]Read More
1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2. Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic 3. […]Read More
Shots: Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share, $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along with royalties on sales of products manufactured in either system Ultragenyx get a non-exclusive license to IP, including know-how and patent applications, regarding its manufacturing […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
